A476060 Share Price Performance
₩14,770.00
8220.00 (125.50%)
Price ₩14,770.00
Share Pricen/a
No trending discussion available.
No recently updated narratives available.
Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Korea.